Tuberculosis-immune reconstitution inflammatory syndrome in HIV: From pathogenesis to prediction

Expert Review of Clinical Immunology

Volumn 10, Issue 5, 2014, Pages 631-645

  Gopalan, Narendran ^a   Andrade, Bruno Bezerril ^b   Swaminathan, Soumya ^a  

^a NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

ART; biomarkers for IRIS; HAART; HIV; IRIS; paradoxical reaction; TB

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; CYCLOSPORIN; CYTOKINE; GAMMA INTERFERON; ICOSANOID; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 6; LEUKOTRIENE; MATRILYSIN; MATRIX METALLOPROTEINASE; MYCOBACTERIUM ANTIGEN; NATALIZUMAB; STEROID; STROMELYSIN; STROMELYSIN 2; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VIRUS RNA;

ANTIGENICITY; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; DISEASE SEVERITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC PREDISPOSITION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; INCIDENCE; INFLAMMATION; MORNING DOSAGE; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PREDICTION; REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE SUBPOPULATION; TUBERCULOSIS; VIRUS LOAD; BIOLOGICAL MODEL; CHEMICALLY INDUCED; HIV INFECTIONS; IMMUNOLOGY; MICROBIOLOGY; PHYSIOLOGY; T LYMPHOCYTE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CYTOKINES; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MODELS, IMMUNOLOGICAL; MYCOBACTERIUM TUBERCULOSIS; T-LYMPHOCYTES; TUBERCULOSIS;

EID: 84898913020     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.892828     Document Type: Review

References (80)

1. Lawn SD, Lipman MC, Easterbrook PJ. Immune reconstitution disease associated with Mycobacterial infections. Curr Opin HIV AIDS 2008;3:425-31
2. Muller M, Simon W, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systemic review and meta analysis. Lancet Infect Dis 2010;10:251-61
3. Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002;81(3): 213-27
4. Narendran G, Andrade BB, Porter BO, et al. Paradoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) in HIV patients with culture confirmed pulmonary tuberculosis in India and the potential role of IL-6 in prediction. PLoS One 2013;8(5):e63541
5. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008;8(8):516-23
6. Murdoch DM, Venter WD, Feldman C, et al. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008;22(5): 601-10
7. Breen RA, Smith CJ, Bettinson H, et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 2004;59:704-7
8. Narita M, Ashkin D, Hollender ES, et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998;158:157-61
9. Sereti I, Rodger AJ, French MA, et al. Biomarkers in immune reconstitution inflammatory syndrome: signals from pathogenesis. Curr Opin HIV AIDS 2010; 5(6):504-10
10. Zaidi I, Peterson K, Jeffries D, et al. Immune reconstitution inflammatory syndrome and the influence of T regulatory cells: a cohort study in The Gambia. PLoS One 2012;7(6):e39213
11. Barber DL, Bruno AB, Sereti I, et al. Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none. Nature 2012;10:150-6
12. Pepper DJ, Marais S, Maartens G, et al. Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis 2009;48:96-107
13. French MA, Price P, Stone SF, et al. Immune restoration disease after antiretroviral therapy. AIDS 2004;18: 1615-27
14. Colebunders R, John L, Huyst V, et al. Tuberculosis immune reconstitution inflammatory syndrome in countries with limited resources. Int J Tuberc Lung Dis 2006; 10(9): 946-53
15. Manabe YC, Campbell JD, Sydnor E, et al. Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr 2007;46(4):456-62
16. Breton G, Duval X, Estellat C, et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004;39:1709-12
17. Narendran G, Swaminathan S. Tuberculosis immune reconstitution inflammatory syndrome: profile of an enigmatic condition. Curr Sci 2013;105(5):657-65
18. Marais S, Meintjes G, Pepper DJ, et al. Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis 2013;56(3):450-60
19. Buckingham SJ, Haddow LJ, Shaw PJ, et al. Immune reconstitution inflammatory syndrome in HIV-infected patients with mycobacterial infections starting highly active anti-retroviral therapy. Clin Radiol 2004;59(6):505-13
20. Swaminathan S, Padmapriyadarsini C, Venkatesan P, et al. Efficacy and safety of once-daily nevirapine-or efavirenz-based antiretroviral therapy in hiv associated tuberculosis: a randomized clinical trial. Clin Infect Dis 2011;53(7):716-24
21. Lawn SD, Myer L, Bekker LG, et al. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007;21: 335-41
22. Lawn SD, Macallan DC. Hypercalcemia: a manifestation of immune reconstitution complicating tuberculosis in an HIV-infected person. Clin Infect Dis 2004;38(1): 154-5
23. Price P, Murdoch DM, Agarwal U, et al. Immune restoration diseases reflect diverse immunopathological mechanisms. Clin Microbiol Rev 2009;22(4):651-63
24. Letang E, Miro JM, Nhampossa T, et al. Incidence and predictors of immune reconstitution inflammatory syndrome in a rural area of Mozambique. PLoS One 2011; 6(2):e16946
25. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011;365(16):1492-501
26. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011;365(16): 1471-81
27. Haddow LJ, Moosa MY, Mosam A, et al. Incidence, clinical spectrum, risk factors and impact of HIV-associated immune reconstitution inflammatory syndrome in South Africa. PLoS One 2012;7(11):e40623
28. Ratnam I, Chiu C, Kandala NB, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type-1 infected cohort. Clin Infect Dis 2006;42:418-27
29. Lawn SD, Meintjes G. Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy. Expert Rev Anti Infect Ther 2011;9(4):415-30
30. Worodria W, Menten J, Massinga-Loembe M, et al. Clinical spectrum, risk factors and outcome of immune reconstitution inflammatory syndrome in patients with tuberculosis-HIV co-infection. Antivir Ther 2012;17(5):841-8
31. Price P, Morahan G, Huang D, et al. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS 2002;16:2043-7
32. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010;362(8):697-706
33. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011;365(16):1482-91
34. Velasco M, Castilla V, Sanz J, et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 2009;50(2):148-52
35. Narendran G, Swaminathan S. Comparing daily vs intermittent regimen of ATT in HIV with pulmonary tuberculosis. 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00933790?term=Daily+Vs +intermittent+ATT+in+HIV&rank=1 [Last accessed 25 January 2014]
36. Revised NACO guidelines for ART initiation in adults. Office memorandum T-11020/36/2005 [Last accessed 4 November 2011]
37. WHO. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. November 2009. Available from: www.who. int/hiv/pub/arv/rapid- advice-art.pdf?ua=1 [Last accessed 25 November 2013]
38. Bourgarit A, Carcelain G, Martinez V, et al. Explosion of tuberculin-specific Th1- responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 2006;20(2):F1-7
39. Battegay M, Nuesch R, Hirschel B, et al. Kaufmann GR Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis 2006;6(5):280-7
40. Renaud M, et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. AIDS 1999;13:669-76
41. Lange CG, Lederman MM. Immune reconstitution with antiretroviral therapies in chronic HIV-1 infection. J Antimicrob Chemother 2003;51:1-4
42. Bourgarit A, Carcelain G, Samri A, et al. Tuberculosis-associated immune restoration syndrome in HIV-1-infected patients involves tuberculin-specific CD4 Th1 cells and KIR-negative gamma delta T cells. J Immunol 2009;183(6):3915-23
43. Antonelli LR, Mahnke Y, Hodge JN, et al. Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome. Blood 2010;116(19): 3818-27
44. Espinosa E, Romero-Rodriguez DP, Cantoral-Diaz MT, et al. Transient expansion of activated CD8+ T cells characterizes tuberculosis-associated immune reconstitution inflammatory syndrome in patients with HIV: a case control study. J Inflamm (Lond) 2013;10(1):21
45. Mahnke YD, Greenwald JH, DerSimonian R, et al. Selective expansion of poly functional pathogen-specific CD4(+) T cells in HIV-1-infected patients with immune reconstitution inflammatory syndrome. Blood 2012;119(13):3105-12
46. Eggena MP, Barughare B, Jones N, et al. depletion of regulatory T cells in HIV infection. J Immunol 2005;174:4407-14
47. Elliott JH, Vohith K, Saramony S, et al. Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy. J Infect Dis 2009;200(11):1736-45
48. Montes M, Cesar S, Dororthy EL. Normalization of Fox P3+regulatory cells in response to effective antiretro viral therapy. J Infect Dis 2011;203:496-9
49. Meintjes G, Wilkinson KA, Rangaka MX, et al. Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 2008;178(10):1083-9
50. Seddiki N, Sasson SC, Santner-Nanan B, et al. Proliferation of weakly suppressive regulatory CD4+ T cells is associated with over-active CD4+ T-cell responses in HIV-positive patients with mycobacterial immune restoration disease. Eur J Immunol 2009;39(2):391-403
51. Dsouza M, Fontenot AP, Mack DG, et al. Programmed death 1 expression on HIV- specific CD4 T cells is driven by viral replication and associated T cell dysfunction. J Immunol 2007;179(3):1979-87
52. Stewart CA, Vivier E, Colonna M. Strategies of natural killer cell recognition and signaling. Curr Top Microbiol Immunol 2006;298:1-21
53. Mavillo D, Benjamin J, Daucher, et al. Natural killer cells in HIV-infcetion; dichotomus effects of viraemia o ninhibitory and activating receptors and their function correlates. Proc Natl Acad Sci USA 2003; 100(25):15011-16
54. Pean P, Nerrienet E, Madec Y, et al. Natural killer cell degranulation capacity predicts early onset of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients with tuberculosis. Blood 2012;119(14):3315-20
55. Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010;9(4): 438-46
56. Tadokera R, Meintjes G, Skolimowska KH, et al. Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur Respir J 2011; 37(5):1248-59
57. Tan DB, Yong YK, Tan HY, et al. Immunological profiles of immune restoration disease presenting as mycobacterial lymphadenitis and cryptococcal meningitis. HIV Med 2008; 9(5):307-16
58. Oliver BG, Elliott JH, Price P, et al. Mediators of innate and adaptive immune responses differentially affect immune restoration disease associated with Mycobacterium tuberculosis in HIV patients beginning antiretroviral therapy. J Infect Dis 2010;202(11):1728-37
59. Gierens H, Nauck M, Roth M, et al. Interleukin-6 stimulated DL receptor gene expression via activation of sterol-responsive and Sp 1 binding elements. Arterioscler Thromb Vasc Biol 2000;20:1777-83
60. Worsley CM, Suchard MS, Stevens WS, et al. Multi-analyte profiling of ten cytokines in South African HIV-infected patients with immune reconstitution inflammatory syndrome (IRIS). AIDS Res Ther 2010;7:36
61. Volkman HE, Pozos TC, Zheng J, et al. Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science 2010;327: 466-9
62. Tadokera R, Meintjes G, Wilkinon KA, et al. Matrix metalloproteinases and tissue damage in HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur J Immunol 2014;44(1): 127-36
63. Manabe YC, Breen RAM, Perti T, et al. et al. Unmasking tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. J Infect Dis 2009;199:437-44
64. Haddow LJ, Dibben O, Moosa MY, et al. Circulating inflammatory biomarkers can predict and characterize tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2011;25(9):1163-74
65. Ianello A, Boulassel MR, Samarani S, et al. HIV-1 causes imbalance in the production of interleukin-18 and its natural antagonist in HIV infected individuals; implications of enhanced viral replication. J Infect Dis 2010;201:608-17
66. Michailides C, Pozniak AL, Mandalia S, et al. Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir Ther 2005;10:417-22
67. Lawn SD, Edwards DJ, Kranzer K, et al. Urine Lipoarabinamannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS 2009;23:1875-80
68. Porter BO, Ouedraogo GL, Hodge JN, et al. D-dimer and CRP levels are elevated prior to antiretroviral treatment in patients who develop IRIS. Clin Immunol 2010; 136(1):42-50
69. Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010;24(15):2381-90
70. Brunel AS, Reynes J, Tuaillon E, et al. Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS. AIDS 2012;26(16):2110-12
71. Meintjes G, Skolimowska KH, Wilkinson KA, et al. Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 2012;186(4): 369-77
72. Hennigan S, Kavanaugh A. Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. Ther Clin Risk Manag 2008;4:767-75
73. Hardwick C, White D, Morris E, et al. Montelukast in the treatment of HIV associated immune reconstitution disease. Sex Transm Infect 2006;82:513-14
74. Sun HY, Singh N. Potential role of statins for the management of immune reconstitution syndrome. Med Hypotheses 2010;76(3):307-10
75. Knight RL, Allen DR, Birch HL, et al. Development of CXCR3 antagonists. Part 4: discovery of 2-amino-(4-tropinyl) quinolines. Bioorg Med Chem Lett 2008;18:629-33
76. Funderburg N, Kalinowska M, Eason J, et al. Effects of Mraviroc and Efavirenz on markers of immune activation and inflammation and associations with CD4+ cells rise in HIV infected patients. PLoS One 2010;5(10):e13188
77. Sierra-Madero JG, et al. Maraviroc does not prevent IRIS in high risk subjects initiating ART. (CADIRIS Trial) Abstract 182LB. 20th Conference on retrovirus and opportunistic infections. 2013.Available from: www.hivandhepatitis.com/hiv-aids/hiv-aids-topics/hiv-prevention/ 4050-croi-2013-maraviroc-does-not-prevent-immune-reconstitution-syndrome [Last accessed 30 January 2014]
78. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006;355(10): 1018-28
79. Marais S, Scholtz P, Pepper DJ, et al. Neuroradiological features of the tuberculosis-associated immune reconstitution inflammatory syndrome. Int J Tuberc Lung Dis 2010;14(2):188-96
80. Manosuthi W, Kiertiburanakul S, Phoorisri T, et al. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect 2006;53(6):357-63